Please use this identifier to cite or link to this item:
|Title:||Molecular drivers of breast implant-associated anaplastic large cell lymphoma|
|Other Authors:||Thomas, E. R.|
Prince, H. M.
Anaplastic Large Cell Lymphoma
Breast Implant Associated Anaplastic Large Cell Lymphoma
T-Cell Lymphoproliferative Disorder
ALK-Negative Systemic Anaplastic Large Cell Lymphoma
|Citation:||Plast Reconstr Surg. 2019 Mar;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):59S-64S. doi: 10.1097/PRS.0000000000005570|
|Abstract:||Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell lymphoproliferative disorder occurring in patients with breast implants. Genomic characterization performed in BIA-ALCL to date has demonstrated qualitatively similar molecular abnormalities to those seen in its more common counterpart [ALK-negative systemic anaplastic large cell lymphoma (sALCL)] including JAK/STAT activation and MYC/TP53 dysregulation. Despite these observed similarities at the molecular level, the outcomes of sALCL and BIA-ALCL are markedly different with sALCL typically associated with an aggressive course and inferior outcomes compared with BIA-ALCL. This review describes the findings of high-throughput sequencing and other genomic characterization to date in BIA-ALCL and the insights these studies have given into the molecular drivers of this rare lymphoma subtype.|
|Journal Title:||Plastic and Reconstructive Surgery|
|Affiliated Organisations:||Parkville and East Melbourne, Victoria, Australia From the Department of Pathology|
Peter MacCalllum Cancer Centre, University of Melbourne
Sir Peter MacCallum Department of Oncology, University of Melbourne
|Appears in Collections:||General Surgery and Gastroenterology|
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.